从泊沙康唑混悬液换用片剂可提高白血病患者的血清药物水平，且无临床相关肝毒性。
Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.
作者信息
Jung Dong Sik, Tverdek Frank P, Kontoyiannis Dimitrios P
机构信息
Departments of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Division of Infectious Diseases, Department of Internal Medicine, Dong-A University College of Medicine, Busan, South Korea.
Pharmacy Clinical Programs, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
出版信息
Antimicrob Agents Chemother. 2014 Nov;58(11):6993-5. doi: 10.1128/AAC.04035-14. Epub 2014 Sep 8.
Abstract
We evaluated posaconazole serum concentrations and hepatotoxicity in 12 leukemia patients who transitioned from posaconazole suspension to tablets. Patients who switched to tablets had significantly increased posaconazole concentrations (median: suspension, 748 ng/ml; tablet, 1,910 ng/ml; P < 0.01) without clinically relevant hepatotoxicity.
摘要
我们评估了12例从泊沙康唑混悬液转换为片剂的白血病患者的泊沙康唑血清浓度和肝毒性。转换为片剂的患者泊沙康唑浓度显著升高（中位数：混悬液，748纳克/毫升；片剂，1910纳克/毫升；P<0.01），且无临床相关肝毒性。
相似文献
1
Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.从泊沙康唑混悬液换用片剂可提高白血病患者的血清药物水平，且无临床相关肝毒性。
Antimicrob Agents Chemother. 2014 Nov;58(11):6993-5. doi: 10.1128/AAC.04035-14. Epub 2014 Sep 8.
2
Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.单剂量 I 期研究评估泊沙康唑新片剂和胶囊剂与口服混悬剂的药代动力学。
Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201. doi: 10.1128/AAC.00222-12. Epub 2012 May 21.
3
Efficacy, safety and feasibility of antifungal prophylaxis with posaconazole tablet in paediatric patients after haematopoietic stem cell transplantation.泊沙康唑片用于造血干细胞移植术后儿科患者抗真菌预防的疗效、安全性及可行性
J Cancer Res Clin Oncol. 2017 Jul;143(7):1281-1292. doi: 10.1007/s00432-017-2369-7. Epub 2017 Mar 3.
4
Phase 1b study of new posaconazole tablet for prevention of invasive fungal infections in high-risk patients with neutropenia.新型泊沙康唑片用于预防中性粒细胞减少高危患者侵袭性真菌感染的1b期研究。
Antimicrob Agents Chemother. 2014 Oct;58(10):5758-65. doi: 10.1128/AAC.03050-14. Epub 2014 Jul 21.
5
Posaconazole plasma exposure correlated to intestinal mucositis in allogeneic stem cell transplant patients.泊沙康唑的血浆暴露量与异基因干细胞移植患者的肠道粘膜炎相关。
Eur J Clin Pharmacol. 2016 Aug;72(8):953-63. doi: 10.1007/s00228-016-2057-6. Epub 2016 Apr 11.
6
Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.与泊沙康唑混悬剂相比，泊沙康唑片治疗并未降低泊沙康唑谷浓度的变异性。
Antimicrob Agents Chemother. 2019 Sep 23;63(10). doi: 10.1128/AAC.00484-19. Print 2019 Oct.
7
Posaconazole delayed-release tablets in paediatric haematology-oncology patients.泊沙康唑延迟释放片在儿科血液肿瘤患者中的应用。
Mycoses. 2020 Jun;63(6):604-609. doi: 10.1111/myc.13084. Epub 2020 Apr 15.
8
A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.泊沙康唑新固体口服片剂制剂：一项在健康志愿者中考察单剂量和多剂量递增药代动力学和安全性的随机临床试验。
J Antimicrob Chemother. 2012 Nov;67(11):2725-30. doi: 10.1093/jac/dks268. Epub 2012 Jul 24.
9
Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.服用缓释片与口服混悬液的患者中泊沙康唑血药浓度的回顾性比较
Antimicrob Agents Chemother. 2015 Aug;59(8):4914-8. doi: 10.1128/AAC.00496-15. Epub 2015 Jun 8.
10
Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.对急性髓系白血病患者在转换为泊沙康唑片剂制剂前后预防侵袭性真菌感染时达到目标药物水平情况的回顾性分析。
J Oncol Pharm Pract. 2018 Dec;24(8):599-603. doi: 10.1177/1078155217722405. Epub 2017 Aug 2.
引用本文的文献
1
Effectiveness of posaconazole as primary prophylaxis in allogeneic hematopoietic stem cell transplantation.泊沙康唑作为异基因造血干细胞移植主要预防用药的有效性
Int J Hematol. 2025 Sep 3. doi: 10.1007/s12185-025-04059-0.
2
Compare the efficacy of antifungal agents as primary therapy for invasive aspergillosis: a network meta-analysis.比较抗真菌药物作为侵袭性曲霉病初始治疗的疗效：一项网状Meta分析。
BMC Infect Dis. 2024 Jun 12;24(1):581. doi: 10.1186/s12879-024-09477-9.
3
Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Model of () Infection.唑类口服药物与米替福新联合治疗 () 感染模型的效价和临床前证据。
Antimicrob Agents Chemother. 2022 Jan 18;66(1):e0142521. doi: 10.1128/AAC.01425-21. Epub 2021 Oct 25.
4
American Society of Transplantation and Cellular Therapy Series, 2: Management and Prevention of Aspergillosis in Hematopoietic Cell Transplantation Recipients.美国移植与细胞治疗学会系列，第2部分：造血细胞移植受者曲霉病的管理与预防
Transplant Cell Ther. 2021 Mar;27(3):201-211. doi: 10.1016/j.jtct.2020.10.003.
5
Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare.将口服药物开发提升到新高度：IMI资助的OrBiTo项目对患者医疗保健的影响。
Front Med (Lausanne). 2021 Mar 5;8:480706. doi: 10.3389/fmed.2021.480706. eCollection 2021.
6
Gynecomastia and hypertension in a patient treated with posaconazole.一名接受泊沙康唑治疗的患者出现男性乳腺增生和高血压。
Clin Case Rep. 2020 Sep 28;8(12):3158-3161. doi: 10.1002/ccr3.3376. eCollection 2020 Dec.
7
Pharmacokinetics and Pharmacodynamics of Posaconazole.泊沙康唑的药代动力学和药效学。
Drugs. 2020 May;80(7):671-695. doi: 10.1007/s40265-020-01306-y.
8
Pharmacokinetics and Safety of Posaconazole Tablet Formulation in Chinese Participants at High Risk for Invasive Fungal Infection.泊沙康唑片剂制剂在有侵袭性真菌感染高危风险的中国参与者中的药代动力学和安全性。
Adv Ther. 2020 May;37(5):2493-2506. doi: 10.1007/s12325-020-01341-x. Epub 2020 Apr 22.
9
Make Sure You Have a Safety Net: Updates in the Prevention and Management of Infectious Complications in Stem Cell Transplant Recipients.确保你有一个安全保障：干细胞移植受者感染性并发症预防与管理的最新进展
J Clin Med. 2020 Mar 21;9(3):865. doi: 10.3390/jcm9030865.
10
Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?抗真菌药物的治疗药物监测：改善患者预后的另一工具？
Infect Dis Ther. 2020 Mar;9(1):137-149. doi: 10.1007/s40121-020-00280-y. Epub 2020 Feb 5.
本文引用的文献
1
Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects.泊沙康唑片的药代动力学：在健康受试者中，合并用药对胃pH值和胃动力的改变无影响。
Antimicrob Agents Chemother. 2014 Jul;58(7):4020-5. doi: 10.1128/AAC.02448-13. Epub 2014 May 5.
2
Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.抗真菌药物的治疗药物监测（TDM）：英国医学真菌学会指南
J Antimicrob Chemother. 2014 May;69(5):1162-76. doi: 10.1093/jac/dkt508. Epub 2013 Dec 29.
3
Multicenter study of posaconazole therapeutic drug monitoring: exposure-response relationship and factors affecting concentration.泊沙康唑治疗药物监测的多中心研究：暴露-反应关系和影响浓度的因素。
Antimicrob Agents Chemother. 2012 Nov;56(11):5503-10. doi: 10.1128/AAC.00802-12. Epub 2012 Aug 13.
4
A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers.泊沙康唑新固体口服片剂制剂：一项在健康志愿者中考察单剂量和多剂量递增药代动力学和安全性的随机临床试验。
J Antimicrob Chemother. 2012 Nov;67(11):2725-30. doi: 10.1093/jac/dks268. Epub 2012 Jul 24.
5
Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension.单剂量 I 期研究评估泊沙康唑新片剂和胶囊剂与口服混悬剂的药代动力学。
Antimicrob Agents Chemother. 2012 Aug;56(8):4196-201. doi: 10.1128/AAC.00222-12. Epub 2012 May 21.
6
Posaconazole treatment in hematology patients: a pilot study of therapeutic drug monitoring.泊沙康唑治疗血液学患者：治疗药物监测的初步研究。
Ther Drug Monit. 2012 Jun;34(3):320-5. doi: 10.1097/FTD.0b013e31824d135c.
7
Relevance of timing for determination of posaconazole plasma concentrations.泊沙康唑血药浓度监测时间的相关性。
Antimicrob Agents Chemother. 2011 Jul;55(7):3621-3. doi: 10.1128/AAC.00062-11. Epub 2011 Apr 18.
8
Fungal infections in leukemia patients: how do we prevent and treat them?白血病患者的真菌感染：我们如何预防和治疗？
Clin Infect Dis. 2010 Feb 1;50(3):405-15. doi: 10.1086/649879.
9
Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial.泊沙康唑治疗对传统疗法难治或不耐受的侵袭性曲霉病患者：一项外部对照试验。
Clin Infect Dis. 2007 Jan 1;44(1):2-12. doi: 10.1086/508774. Epub 2006 Nov 28.
10
A sensitive liquid chromatography and mass spectrometry method for the determination of posaconazole in human plasma.一种用于测定人血浆中泊沙康唑的灵敏液相色谱-质谱联用方法。
J Pharm Biomed Anal. 2007 Jan 4;43(1):228-36. doi: 10.1016/j.jpba.2006.06.011. Epub 2006 Jul 21.
Zotero 插件